Energy News / Shareholders Foundation, Inc.

NASDAQ:OHRP Investor Alert: Investigation over Potential Wrongdoing in Acquisition of OHR Pharmaceutical, Inc.

Via: ReleaseWire

Updated 11:45 AM CST, Mon, January 07,2019

An investigation on behalf of investors of OHR Pharmaceutical, Inc. (NASDAQ: OHRP) in connection with the proposed takeover was announced.

San Diego, CA -- (SBWIRE) -- 01/07/2019 -- An investigation was announced concerning whether the takeover of OHR Pharmaceutical, Inc. is unfair to NASDAQ: OHRP stockholders.

Investors who purchased shares of OHR Pharmaceutical, Inc. (NASDAQ: OHRP) and currently hold any of those NASDAQ: OHRP shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of OHR Pharmaceutical, Inc. breached their fiduciary duties owed to NASDAQ: OHRP investors in connection with the proposed acquisition.

New Yokr based OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. On Jan. 03, 2019 Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) announced that it has entered into a merger agreement with NeuBase Therapeutics, Inc, under which the stockholders of NeuBase would become the majority holders of the combined company.

However, the investigation concerns whether the offer is unfair to NASDAQ: OHRP stockholders. More specifically, the investigation concerns whether the OHR Pharmaceutical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On January 4, 2018, OHR Pharmaceutical, Inc. (NASDAQ: OHRP) shares closed at $0.16 per share.

Those who are current investors in OHR Pharmaceutical, Inc. (NASDAQ: OHRP) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqohrp-investor-alert-investigation-over-potential-wrongdoing-in-acquisition-of-ohr-pharmaceutical-inc-1116979.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com